BR112022007213A2 - Combinação imunogênica, tipo de vacina polivalente, proteína vetorial de mutagênese de ponto fixo, conjugado da dita proteína e seu uso na preparação de vacina - Google Patents

Combinação imunogênica, tipo de vacina polivalente, proteína vetorial de mutagênese de ponto fixo, conjugado da dita proteína e seu uso na preparação de vacina

Info

Publication number
BR112022007213A2
BR112022007213A2 BR112022007213A BR112022007213A BR112022007213A2 BR 112022007213 A2 BR112022007213 A2 BR 112022007213A2 BR 112022007213 A BR112022007213 A BR 112022007213A BR 112022007213 A BR112022007213 A BR 112022007213A BR 112022007213 A2 BR112022007213 A2 BR 112022007213A2
Authority
BR
Brazil
Prior art keywords
protein
vaccine
fixed
point mutagenesis
conjugate
Prior art date
Application number
BR112022007213A
Other languages
English (en)
Inventor
Wang Haomeng
Yan Qiaoling
Chao Shoubai
Mao Huihua
Zhu Tao
Original Assignee
Cansino Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cansino Biologics Inc filed Critical Cansino Biologics Inc
Publication of BR112022007213A2 publication Critical patent/BR112022007213A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMBINAÇÃO IMUNOGÊNICA, TIPO DE VACINA POLIVALENTE, PROTEÍNA VETORIAL DE MUTAGÊNESE DE PONTO FIXO, CONJUGADO DA DITA PROTEÍNA E SEU USO NA PREPARAÇÃO DE VACINA. A presente invenção fornece uma proteína vetorial de mutagênese de ponto fixo e sua aplicação na preparação de vacinas, em que o aminoácido pelo menos 1 local na proteína vetorial é mutado a aminoácidos não naturais contendo bases de azinil ou acetileno. A proteína vetorial de mutagênese de ponto fixo da presente invenção evita uma conjugação excessiva com antigênicos polissacarídica e pode ser utilizada para preparar uma vacina combinada de proteína polissacarídica.
BR112022007213A 2019-10-15 2020-09-25 Combinação imunogênica, tipo de vacina polivalente, proteína vetorial de mutagênese de ponto fixo, conjugado da dita proteína e seu uso na preparação de vacina BR112022007213A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910978406.XA CN110845587B (zh) 2019-10-15 2019-10-15 一种定点突变的载体蛋白及其在制备疫苗中的用途
PCT/CN2020/117825 WO2021073402A1 (zh) 2019-10-15 2020-09-25 一种定点突变的载体蛋白及其在制备疫苗中的用途

Publications (1)

Publication Number Publication Date
BR112022007213A2 true BR112022007213A2 (pt) 2022-08-02

Family

ID=69596763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007213A BR112022007213A2 (pt) 2019-10-15 2020-09-25 Combinação imunogênica, tipo de vacina polivalente, proteína vetorial de mutagênese de ponto fixo, conjugado da dita proteína e seu uso na preparação de vacina

Country Status (12)

Country Link
US (1) US20230111095A1 (pt)
EP (1) EP4047013A4 (pt)
JP (1) JP7366333B2 (pt)
KR (1) KR20220082035A (pt)
CN (1) CN110845587B (pt)
AU (1) AU2020366472B2 (pt)
BR (1) BR112022007213A2 (pt)
CA (1) CA3154849A1 (pt)
CO (1) CO2022006035A2 (pt)
EC (1) ECSP22038109A (pt)
MX (1) MX2022004638A (pt)
WO (1) WO2021073402A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845587B (zh) * 2019-10-15 2021-06-29 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
CN111533792B (zh) * 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
TW202306969A (zh) * 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
CN113651876B (zh) * 2021-08-18 2024-02-02 成都齐碳科技有限公司 孔蛋白单体的突变体、蛋白孔及其应用
CN114456275B (zh) * 2022-01-27 2023-05-12 苏州大学 一种多位点单泛素修饰组蛋白的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553246B (zh) * 2006-08-07 2019-05-21 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
WO2009035494A2 (en) * 2007-07-30 2009-03-19 The Scripps Research Institute Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
US20150072396A1 (en) * 2011-03-04 2015-03-12 Life Technologies Corporation Compounds and Methods for Conjugation of Biomolecules
CN102159032B (zh) 2011-03-25 2013-06-19 罗小亚 一种采用模切机制造挠性印刷线路板的工艺方法
CN103110940B (zh) * 2013-02-06 2015-06-03 中国科学院过程工程研究所 一种基于点击化学的肺炎多糖结合疫苗及其制备方法
WO2017030156A1 (ja) * 2015-08-19 2017-02-23 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
CN106929482A (zh) 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
WO2018126229A2 (en) * 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
CN108904798A (zh) * 2018-07-17 2018-11-30 成都安特金生物技术有限公司 一种多糖蛋白结合疫苗及其鉴别方法
CN110845587B (zh) * 2019-10-15 2021-06-29 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途

Also Published As

Publication number Publication date
JP2022552403A (ja) 2022-12-15
CN110845587B (zh) 2021-06-29
EP4047013A4 (en) 2022-12-14
AU2020366472A1 (en) 2022-05-12
CO2022006035A2 (es) 2022-05-20
AU2020366472B2 (en) 2024-01-04
ECSP22038109A (es) 2022-07-29
MX2022004638A (es) 2022-07-11
EP4047013A1 (en) 2022-08-24
KR20220082035A (ko) 2022-06-16
US20230111095A1 (en) 2023-04-13
JP7366333B2 (ja) 2023-10-23
CN110845587A (zh) 2020-02-28
CA3154849A1 (en) 2021-04-22
WO2021073402A1 (zh) 2021-04-22

Similar Documents

Publication Publication Date Title
BR112022007213A2 (pt) Combinação imunogênica, tipo de vacina polivalente, proteína vetorial de mutagênese de ponto fixo, conjugado da dita proteína e seu uso na preparação de vacina
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
Valadez Sierra et al. Emotional intelligence and its relationship with gender, academic performance and intellectual abilities of undergraduates.
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
BR112021020777A2 (pt) Vacina de subunidade do csfv
CY1122961T1 (el) Τοπικα φαρμακευτικα και ιατροτεχνολογικα παρασκευασματα που περιεχουν συνδυασμους σουκραλφατης, υαλουρονικου οξεος, αργινινης και ενος φυσικου υγραντικου παραγοντα
Vicente et al. Encefalitis anti-NMDA y enfermería al alta
BR112017003486A2 (pt) métodos para expressar uma molécula antigênica ou uma parte da mesma e gerar uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e molécula antigênica, molécula antigênica, agente fotossensibilizante e citocina, produto, e, kit
GB258201A (en) Improvements in ball and socket joints
AR114291A1 (es) Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos
GB365795A (en) Improvements in and relating to hair slides or fastenings
AR020403A1 (es) Formulacion de acidos nucleicos y acemanano
Theran León et al. Infarto de miocardio alérgico por consumo de ciruela, presentación de caso clínico.
Thomas X.—Four new Amazonian monkeys
Secfion USHE END-OF-YEAR ENROLLMENT REPORT
BR0316271A (pt) Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
D Restrepo et al. Estudio sobre la fluoruración de la sal
BR132019012085E2 (pt) composição de batom com propriedades funcionais
USD141062S (en) Design for a toy
BR132019008298E2 (pt) composição de batom com propriedades funcionais
Fournelle et al. Enfermedades diarreicas en Colombia: informe de una encuesta bacteriológica
BR0009051A (pt) Utilização de uma fração de membrana de klebsiella pneumoniae associada a um antìgeno ou hapteno, e, composição farmacêutica
BR112021026409A2 (pt) Formulação compreendendo o anticorpo anti-lag-3, método para preparo e uso do mesmo
Balloy et al. 084 Experimental acute lung disease due to Pseudomonas aeruginosa: analysis of the role of flagellin
Barra et al. A new species of Delamarephorura Weiner & Najt, 1999 (Collembola, Tullbergiidae) from Cape Province (South Africa)